Trials / Completed
CompletedNCT01352585
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 47 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anagrelide hydrochloride | 0.5 mg hard capsules, dosing decisions will be made by the treating physician |
Timeline
- Start date
- 2011-07-19
- Primary completion
- 2013-09-19
- Completion
- 2013-09-19
- First posted
- 2011-05-12
- Last updated
- 2021-07-30
- Results posted
- 2014-07-29
Locations
10 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01352585. Inclusion in this directory is not an endorsement.